BioSpace News Archive

Seegene Inc., South Korea’s leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays.

Kodiak Sciences Inc. announced new seven-year performance stock option awards under a Long-Term Performance Incentive Plan for named executive officers as well as other eligible Kodiak employees, subject to stockholder approval of the LTPIP at a special meeting expected to be held in October.

Tyber Medical, LLC, a leading orthopedic device manufacturer providing private label orthopedic implants for the trauma, extremity, and spine markets, received its second and largest U.S. Food and Drug Administration 510 clearance for its expanded line of anatomical plating systems.

MediciNova, Inc. announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD” has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases to be held November 12 - 15, 2021.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will issue its financial results for the quarter ended June 30, 2021, on Tuesday, September 7, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day.

Lumenis announced the completion of the sale of its Surgical business to Boston Scientific Corporation, a leading global medical device manufacturer, in a transaction valued at $1.07B.

Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of John Strafford, Ph.D., to the newly created role of Senior Vice President, Business Development, Alliance Management and New Product Development, effective immediately.

Landos Biopharma, Inc., a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, announced that company management will participate in five upcoming virtual investor conferences in September:

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 32,130 ordinary shares of Nabriva Therapeutics as an inducement to three newly-hired employees.